Inhibitory effects of epinastine on chemokine production and MHC class II/CD54 expression in keratinocytes

Journal of Dermatological Science

Volumn 45, Issue 2, 2007, Pages 144-146

  Kobayashi, Miwa ^a   Kabashima, Kenji ^a   Tokura, Yoshiki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; EPINASTINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; MACROPHAGE DERIVED CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ATOPIC DERMATITIS; CELL POPULATION; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; HUMAN; JAPAN; KERATINOCYTE; LETTER; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PSORIASIS VULGARIS; T LYMPHOCYTE;

CELLS, CULTURED; CHEMOKINES; DIBENZAZEPINES; HISTAMINE H1 ANTAGONISTS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMIDAZOLES; INTERCELLULAR ADHESION MOLECULE-1; KERATINOCYTES;

EID: 33846249352     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2006.09.004     Document Type: Letter

References (10)

1. Amon U., Gibbs B.F., Buss G., and Nitschke M. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res 49 (2000) 112-116
2. Ito J., Asano K., Tryka E., et al. Suppressive effects of co-stimulatory molecule expressions on mouse splenocytes by anti-allergic agents in vitro. Mediators Inflamm 9 (2000) 69-75
3. Matsukura M., Yajima A., Yamazaki F., et al. Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis. Skin Pharmacol Appl Skin Physiol 16 (2003) 405-410
4. Kohyama T., Yakizawa H., Akiyama N., et al. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun 230 (1997) 125-128
5. Sangjae B., Hamasaki Y., and Katayama I. Inhibitory effects of epinastine chloride on histamine: induced eotaxin production in normal human fibroblasts. Jpn Pharmacol Ther 30 (2002) 97-102 (in Japanese)
6. Tasaka K. Epinastine: an update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases. Drugs Today 36 (2000) 735-757
7. Masutani M., Ueda H., Takeuchi M., et al. Clinical study of WAL801CL on psoriasis vulgaris with pruritus. J Clin Ther Med 8 Suppl 1 (1992) 87-95 (in Japanese)
8. Kobayashi M., Shimauchi T., Hino R., and Tokura Y. Roxithromycin downmodulates Th2 chemokine production by keratinocytes and chemokine receptor expression on Th2 cells; its dual inhibitory effects on the ligands and the receptor. Cell Immunol 228 (2004) 27-33
9. Kobayashi M., and Tokura Y. Preferential downmodulation of certain chemokines by fexofenadine in human keratinocytes. J Dermatol Sci 38 (2005) 67-69
10. Tokura Y., Kobayashi M., Ito T., et al. Anti-allergic drug olopatadine suppresses murine contact hypersensitivity and downmodulates antigen-presenting ability of epidermal Langerhans cells. Cell Immunol 224 (2003) 47-54